Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment
2010

Guidelines for the Treatment of Mucopolysaccharidosis I, II, and VI

Sample size: 200 publication Evidence: high

Author Information

Author(s): Roberto Giugliani, Andressa Federhen, Maria Verônica Muñoz Rojas, Taiane Vieira, Osvaldo Artigalás, Louise Lapagesse Pinto, Ana Cecília Azevedo, Angelina Acosta, Carmen Bonfim, Charles Marques Lourenço, Chong Ae Kim, Dafne Horovitz, Denize Bonfim, Denise Norato, Diane Marinho, Durval Palhares, Emerson Santana Santos, Erlane Ribeiro, Eugênia Valadares, Fábio Guarany, Gisele Rosone de Lucca, Helena Pimentel, Isabel Neves de Souza, Jordão Neto Correa, José Carlos Fraga, José Eduardo Goes, José Maria Cabral, José Simionato, Juan Jr. Llerena, Laura Jardim, Liane Giuliani, Luiz Carlos Santana da Silva, Mara L. Santos, Maria Angela Moreira, Marcelo Kerstenetzky, Márcia Ribeiro, Nicole Ruas, Patricia Barrios, Paulo Aranda, Rachel Honjo, Raquel Boy, Ronaldo Costa, Carolina Souza, Flavio F. Alcantara, Silvio Gilberto A. Avilla, Simone Fagondes, Ana Maria Martins

Primary Institution: Serviço de Genética Médica, Hospital de Clínicas de Porto Alegre

Conclusion

The study provides comprehensive guidelines for the treatment of mucopolysaccharidoses, emphasizing the importance of enzyme replacement therapy and multidisciplinary care.

Supporting Evidence

  • Over 200 patients in Brazil have been treated with enzyme replacement therapy for MPS I, II, and VI.
  • Enzyme replacement therapy has significantly improved the management of mucopolysaccharidoses.
  • Multidisciplinary care is essential for the effective treatment of patients with MPS.

Takeaway

Mucopolysaccharidoses are rare diseases that can be treated with special enzyme therapies, and many doctors in Brazil are now experienced in helping patients with these conditions.

Methodology

The guidelines were drafted by a multidisciplinary team of Brazilian professionals with experience in treating MPS, based on clinical trials and available literature.

Limitations

The guidelines may not cover all aspects of treatment due to the evolving nature of medical knowledge and practices.

Participant Demographics

The guidelines are based on the experiences of Brazilian medical centers treating over 200 patients with MPS I, II, and VI.

Digital Object Identifier (DOI)

10.1590/S1415-47572010005000093

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication